Drug Development Pipeline
Lumacaftor + ivacaftor (Orkambi®)
Restore CFTR Function
Lumacaftor and ivacaftor (Orkambi®) is a combination therapy combining lumacaftor, which is designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface, with ivacaftor, which helps improve the function of the protein as a chloride channel on the cell surface.
The FDA has approved the use of Orkambi® in people with CF who have two copies of the F508del CFTR mutation and are 2 years and older.
A phase 3 study of Orkambi® in children ages 12 months to less than 24 months is underway.
Vertex Pharmaceuticals developed this drug with funding from the Cystic Fibrosis Foundation. The drug development was conducted within the Therapeutics Development Network.
Recent Lumacaftor + ivacaftor (Orkambi®) Studies
Latest News on Lumacaftor + ivacaftor
August 07, 2018
The U.S. Food and Drug Administration approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 2 to 5 who have two copies of the F508del mutation.
October 31, 2017
The Institute for Clinical and Economic Review (ICER) is developing an assessment of the clinical effectiveness and value of lumacaftor/ivacaftor (Orkambi®) and ivacaftor/tezacaftor (VX-661). The Foundation is sharing input throughout the process to help incorporate the patient and clinical perspective.
September 28, 2016
The U.S. Food and Drug Administration (FDA) approved the use of lumacaftor/ivacaftor (Orkambi®) today for children with cystic fibrosis ages 6 to 11, who have two copies of the F508del mutation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More